Oncotelic Therapeutics Alpha and Beta Analysis
| OTLCDelisted Stock | USD 0.02 0 6.38% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Oncotelic Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Oncotelic Therapeutics over a specified time horizon. Remember, high Oncotelic Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Oncotelic Therapeutics' market risk premium analysis include:
Beta (0.02) | Alpha (0.26) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Oncotelic |
Oncotelic Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Oncotelic Therapeutics market risk premium is the additional return an investor will receive from holding Oncotelic Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncotelic Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Oncotelic Therapeutics' performance over market.| α | -0.26 | β | -0.02 |
Oncotelic Therapeutics Fundamentals Vs Peers
Comparing Oncotelic Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oncotelic Therapeutics' direct or indirect competition across all of the common fundamentals between Oncotelic Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oncotelic Therapeutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oncotelic Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Oncotelic Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oncotelic Therapeutics to competition |
| Fundamentals | Oncotelic Therapeutics | Peer Average |
| Return On Equity | 0.5 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Current Valuation | 31.34 M | 16.62 B |
| Shares Outstanding | 391.11 M | 571.82 M |
| Shares Owned By Insiders | 55.93 % | 10.09 % |
| Number Of Shares Shorted | 662.75 K | 4.71 M |
| Price To Earning | 2.16 X | 28.72 X |
Oncotelic Therapeutics Opportunities
Oncotelic Therapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Oncotelic Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Oncotelic or other otcs. Alpha measures the amount that position in Oncotelic Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Oncotelic Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Oncotelic Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oncotelic Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Oncotelic Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Oncotelic Therapeutics. Please utilize our Beneish M Score to check the likelihood of Oncotelic Therapeutics' management manipulating its earnings.
| 12th of April 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Oncotelic Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |